YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Difference of Efficacy for Oral Hypoglysemic Pharmacotherapy Based on Sasang Constitutional Medicine Among Type II Diabetes Mellitus Patients in Korea

제 2형 당뇨병 환자에서 사상체질에 따른 경구 혈당강하요법의 치료 반응성 및 사용 패턴 평가

  • Kim, Ji Yeon (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Lee, Myung Koo (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Kim, Jung Tae (Kyung Hee University Hospital at Gangdong, Department of Pharmacy) ;
  • Lim, Sung Cil (The Catholic University of Korea, College of Pharmacy, Lab. of Clinical Pharmacy)
  • 김지연 (충북대학교 약학대학 임상약학실) ;
  • 이명구 (충북대학교 약학대학 임상약학실) ;
  • 김정태 (강동경희대병원 약제부) ;
  • 임성실 (가톨릭대학교 약학대학 임상약학실)
  • Received : 2013.11.25
  • Accepted : 2013.12.18
  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Although Korean patients with type 2 diabetes mellitus (T2DM) are generally treated by western medicine, many of them strongly believe in the traditional oriental Sasang constitutional classification and depend on it for food, health supplements, and oriental medicines decision making. Sasang constitutional classification is a part of traditional Korean medicine that divides people into four constitutional types (Tae-Yang: TY, Tae-Eum: TE, So-Yang: SY, and So-Eum: SE), which differ in inherited characteristics such as appearance, personality traits, susceptibility to diseases, and drug responses. It is recommended for T2DM patients to control their blood glucose very well from early stages with drugs and diet. However, many T2DM patients respond differently to their drugs, even though they receive the same medicine. Therefore, the present study investigated whether Sasang constitutional type can explain the therapeutic differences between oral hypoglycemic agents (OHAs) therapy (mono, dual and triple drug therapy). Patients of 618 with T2DM diagnosis and Sasang constitutional type known who received both western and oriental medicine treatment in a hospital between April 2006 and April 2013 retrospectively studied. HbA1c (%) and blood glucose (mg/dl) levels before OHAs therapy and 3 month after were collected for metformin (MET) or sulfonylurea (SU) monotherapy, MET+SU dual therapy, MET+except SU (where was either alpha-glucosidase inhibitor, dipeptidyl peptidase-4 inhibitor, meglitinide or thiazolidinedione) dual therapy, and triple therapy, according to Sasang constitutional type. For statistical analysis, ANOVA was used and paired t-test by SPSS 19.0 where P values less than 0.05 were considered statistically significant. Pattern was similar levels of HbA1c and blood glucose and which was decreased in order of mono, MET+SU dual, MET+except SU dual and triple therapy. In all patients comparison, for the So-yang (SY) constitutional type, either monotherapy was less effective; for Te-eum (TE) type, MET+SU dual therapy was less effective while MET+except SU dual therapy was more effective and the triple therapy was less effective; and for So-eum (SE) type, the triple therapy was more effective. For the management of TE type it is recommended to use drugs except SU when dual therapy is needed, restrict triple therapy and consider dual and insulin therapy; for SY type it is recommended to follow current guidelines; and for SE type it is advisable to skip dual therapy and start the triple therapy early. Finally, the therapeutic response to OHAs is different among Korean T2DM patients with different Sasang constitutional types. Taken together, the choice of effective OHAs therapy for each type is necessary in order to minimize the poor control of blood glucose level, the risk of complications, and the costs from a failure of therapy.

Keywords

References

  1. Ahn, S. Y., Park, S. H., Han, S. R., Ahn, Y. M. and Lee, B. C. : Association between subclinical hypothyroidism and sasang constitution in a Korean population. Exp. Ther. Med. 3, 740 (2012). https://doi.org/10.3892/etm.2012.461
  2. Jang, E., Baek, Y., Park, K. and Lee, S. : Could the Sasang constitution itself be a risk factor of abdominal obesity?, BMC Complement Altern Med. 13, 72 (2013). https://doi.org/10.1186/1472-6882-13-72
  3. Kim, B. Y., Jin, H. J. and Kim, J. Y. : Genome-wide association analysis of Sasang constitution in the Korean population. J. Altern Complement Med. 18, 262 (2012). https://doi.org/10.1089/acm.2010.0764
  4. Choi, K., Lee, J., Yoo, J., Lee, E., Koh, B. and Lee, J. : Sasang constitutional types can act as a risk factor for insulin resistance. Diabetes Res. Clin. Pract. 91, e57 (2011). https://doi.org/10.1016/j.diabres.2010.11.017
  5. Lee, T., Hwang, M., Lee, S., Choe, B. and Song, I. : A study on the prevalence and risk factors of the metabolic syndrome according to sasang constitution. J. Korean Oriental Med. 27, 14 (2006).
  6. Lee, T. G., Koh, B. H. and Lee, S. K. : Sasang constitution as a risk factor for diabetes mellitus: A cross-sectional study. Evid Based Complement Alternat Med. 6, 99 (2009).
  7. Kim, B. Y., Jin, H. J. and Kim, J. Y. : Genome-wide association analysis of Sasang constitution in the Korean population. J. Altern Complement Med. 18, 262 (2012). https://doi.org/10.1089/acm.2010.0764
  8. Won, H. H., Lee, S., Jang, E., Kim, K. K., Park, Y. K., Kim, Y. J., Kim, Y. S., Kim, B. Y., Kim, J. Y. and Kim, J. W. : A genome-wide scan for the Sasang constitution in a Korean family suggests significant linkage at chromosomes 8q11.22-23 and 11q22.1-3. J. Altern Complement Med. 15, 765 (2009). https://doi.org/10.1089/acm.2009.0067
  9. The Diabetes Control and Complications Trial Research Group : The relationship of glycemic exposure (HbA1c) to the risk of evelopment and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968 (1995). https://doi.org/10.2337/diab.44.8.968
  10. UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837, (1998). https://doi.org/10.1016/S0140-6736(98)07019-6
  11. 대한당뇨병학회 진료지침위원회, "당뇨병 진료 지침 2011".
  12. Ko, S. H., Kim, D. J., Oh, S. J., Lee, H. J., Shim, K. H., Woo, M. H., Kim, J. Y., Kim, N. H., Kim, J. T., Kim, C. H., Kim, H. J., Jeong, I. K., Hong, E. G., Cho, J. H., Mok, J. O., Yoon, K. H. and Kim, S. R. : 2011 Clinical practice guidelines for typer 2 diabetes in Korea. The Journal of Korean Diabetes 12, 183 (2011). https://doi.org/10.4093/jkd.2011.12.4.183
  13. 보건복지부, 질병관리본부, "2010 국민건강통계" p. 72-73.
  14. Higashibata, T., Naito, M., Mori, A., Ozawa, N., Furuta, M., Tsuchiya, R., Koyama, E., Morita, E., Kawai, S., Okada, R., Yin, G., Wakai, K. and Hamajima, N. : DPP4 genetic variants influences baseline prostate-specific antigen levels. Nagoya J. Med. Sci. 75, 73 (2013).
  15. Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S. and Cho, Y. M. : Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non- Asians: a systematic review and meta-analysis. Diabetologia 56, 696 (2013). https://doi.org/10.1007/s00125-012-2827-3
  16. Holstein, A. and Beil, W. : Oral antidiabetic drug metabolismpharmacogenomics and drug interactions. Expert. Opin. Drug. Metab. Toxicol. 5, 225 (2009). https://doi.org/10.1517/17425250902806424
  17. Cha, S. W., Koo, I. H., Park, B. L., Jeong, S. K., Choi, S. M., Kim, K. S., Shin, H. D. and Kim, J. Y. : Genetic effects of FTO and MC4R polymorphisms on body mass in constitutional types. Evid Based Complement Alternat Med. 2011, 106390 (2011).
  18. Song, K. H., Yu, S. G. and Kim, J. Y. : Prevalence of metabolic syndrome according to sasang constitutional medicine in Korean subjects. Evid Based Complement Alternat Med. 2012, 646794 (2012).
  19. Lee, T. G., Koh, B. H. and Lee, S. K. : Sasang constitution as a risk factor for diabetes mellitus: A cross-sectional study. Evid Based Complement Alternat Med. 6, 99 (2009).
  20. Roberts, V. L., Stewart, J., Issa, M., Lake, B. and Melis, R. : Triple therapy with glimepiride in patients with type 2 diabetes mellitusinadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, doubleblind, placebo-controlled, parallel group study. Clin Ther. 27, 1535 (2005). https://doi.org/10.1016/j.clinthera.2005.10.017
  21. Pareek, A., Chandurkar, N., Zawar, S. and Agrawal, N. : Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. Am. J. Ther. 17, 559 (2010). https://doi.org/10.1097/MJT.0b013e3181c6c0f9
  22. Fonseca, V., Rosenstock, J., Patwardhan, R. and Salzman, A. : Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283, 1695 (2000). https://doi.org/10.1001/jama.283.13.1695
  23. Panikar, V., Chandalia, H. B., Joshi, S. R., Fafadia, A. and Santvana, C. : Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. J. Assoc. Physicians India 51, 1061 (2003).